What is a stock summary page? Click here for an overview.
Business Description
DexCom Inc
NAICS : 325413
SIC : 5047
ISIN : US2521311074
Compare
Compare
Traded in other countries / regions
DXCM.USA0A4M.UKD1EX34.BrazilDXCM.MexicoDC4.GermanyDXCM.Austria IPO Date
2021-07-12Description
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1 | |||||
| Equity-to-Asset | 0.32 | |||||
| Debt-to-Equity | 1.23 | |||||
| Debt-to-EBITDA | 2.74 | |||||
| Interest Coverage | 31.58 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 5.23 | |||||
| Beneish M-Score | -2.64 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 19.6 | |||||
| 3-Year EBITDA Growth Rate | 37.5 | |||||
| 3-Year EPS without NRI Growth Rate | 45.7 | |||||
| 3-Year FCF Growth Rate | 131 | |||||
| 3-Year Book Growth Rate | 0.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 22.79 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 15.03 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 26.6 | |||||
| 9-Day RSI | 31.63 | |||||
| 14-Day RSI | 33.49 | |||||
| 3-1 Month Momentum % | 12.13 | |||||
| 6-1 Month Momentum % | 41.66 | |||||
| 12-1 Month Momentum % | -33.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.47 | |||||
| Quick Ratio | 1.28 | |||||
| Cash Ratio | 0.88 | |||||
| Days Inventory | 130.36 | |||||
| Days Sales Outstanding | 88.79 | |||||
| Days Payable | 69.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.2 | |||||
| Shareholder Yield % | 3.16 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 60.46 | |||||
| Operating Margin % | 14.88 | |||||
| Net Margin % | 14.29 | |||||
| FCF Margin % | 15.69 | |||||
| ROE % | 26.6 | |||||
| ROA % | 8.9 | |||||
| ROIC % | 20.52 | |||||
| 3-Year ROIIC % | 13.69 | |||||
| ROC (Joel Greenblatt) % | 54.1 | |||||
| ROCE % | 15.93 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 47.37 | |||||
| Forward PE Ratio | 32.91 | |||||
| PE Ratio without NRI | 40.08 | |||||
| Shiller PE Ratio | 137.08 | |||||
| Price-to-Owner-Earnings | 44.36 | |||||
| PEG Ratio | 1.25 | |||||
| PS Ratio | 6.92 | |||||
| PB Ratio | 12.59 | |||||
| Price-to-Tangible-Book | 13.38 | |||||
| Price-to-Free-Cash-Flow | 44.36 | |||||
| Price-to-Operating-Cash-Flow | 28.24 | |||||
| EV-to-EBIT | 36.5 | |||||
| EV-to-Forward-EBIT | 32.81 | |||||
| EV-to-EBITDA | 28.09 | |||||
| EV-to-Forward-EBITDA | 19.49 | |||||
| EV-to-Revenue | 6.59 | |||||
| EV-to-Forward-Revenue | 5.77 | |||||
| EV-to-FCF | 42.13 | |||||
| Price-to-GF-Value | 0.46 | |||||
| Price-to-Projected-FCF | 4.4 | |||||
| Price-to-Median-PS-Value | 0.47 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.6 | |||||
| Price-to-Graham-Number | 4.88 | |||||
| Earnings Yield (Greenblatt) % | 2.74 | |||||
| FCF Yield % | 2.37 | |||||
| Forward Rate of Return (Yacktman) % | 21.27 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
DexCom Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3,739.482 | ||
| EPS (TTM) (€) | 1.325 | ||
| Beta | 0.4 | ||
| 3-Year Sharpe Ratio | 0.16 | ||
| 3-Year Sortino Ratio | 0.25 | ||
| Volatility % | 52.35 | ||
| 14-Day RSI | 33.49 | ||
| 14-Day ATR (€) | 2.087245 | ||
| 20-Day SMA (€) | 68.9165 | ||
| 12-1 Month Momentum % | -33.46 | ||
| 52-Week Range (€) | 58.07 - 130.7 | ||
| Shares Outstanding (Mil) | 392.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
DexCom Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
DexCom Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
DexCom Inc Frequently Asked Questions
What is DexCom Inc(WBO:DXCM)'s stock price today?
The current price of WBO:DXCM is €63.82. The 52 week high of WBO:DXCM is €130.70 and 52 week low is €58.07.
When is next earnings date of DexCom Inc(WBO:DXCM)?
The next earnings date of DexCom Inc(WBO:DXCM) is 2025-04-25 Est..
Does DexCom Inc(WBO:DXCM) pay dividends? If so, how much?
DexCom Inc(WBO:DXCM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers